Health
Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says
The newly FDA approved Alzheimer’s treatment Leqembi is prepared at Abington Neurological Associates in Abington, PA., on Tuesday, November 7, 2023. Hannah Yoon | The Washington Post | Getty Images The breakthrough Alzheimer’s drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term, […]
Read More
Lost in the market’s sharp rotation out of tech stocks is a really bullish call on major banks
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Market slides : The S & P 500 gave back earlier gains and fell throughout Tuesday afternoon, led lower by the mega-cap tech stocks. Ahead of the […]
Read More
Pfizer beats earnings estimates, hikes full-year outlook as drugmaker cuts costs
Kena Betancur | Corbis News | Getty Images Pfizer on Thursday reported second-quarter revenue and adjusted earnings that blew past expectations and raised its full-year outlook, benefiting from its broad cost-cutting program, better-than-expected sales of its Covid antiviral pill Paxlovid and strong non-Covid product sales. The company now expects to book adjusted earnings of $2.45 to $2.65 […]
Read More
We’re encouraged by Abbott stock trading but discouraged by moves in Honeywell
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Market moves: The S & P 500 was on track for small gains following a solid rally last Friday. There’s still some market rotation happening, but […]
Read More
Here are JPMorgan’s top drug stock picks into earnings
JPMorgan is eyeing a few drug manufacturers ahead of their earnings reports as investors continue to sell out of major technology firms. Major market trends in the first half of 2024 have shifted and sparked a rotation out of large technology stocks into less-loved areas of the market, including value stocks and small caps. The […]
Read More
Jim Cramer’s advice on Abbott Labs stock after a nearly $500 million baby formula verdict
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. Wall Street was lower after Friday’s rebound in a wild week that featured rotations in and out of tech. It’s a busy week ahead with a Fed meeting, 14 earnings […]
Read More
We’re making a flurry of moves: trimming 2 stocks and buying 2 others that have lagged
We’re making four trades Monday morning. Shortly after the opening bell, we will be selling 100 shares of Danaher at roughly $274.13. Following the trade, Jim Cramer’s Charitable Trust will own 475 shares of Danaher, decreasing its weighting in the portfolio to 4% from 4.84%. In addition, we will be selling 20 shares of Salesforce at […]
Read More
FDA approves new blood test to screen for colon cancer
The Food and Drug Administration on Monday approved Guardant Health’s blood test, called Shield, to screen for colon cancer. The test isn’t meant to replace colonoscopies, but is generating enthusiasm among doctors who say it has the potential to boost the dismal rate of screenings for the second-highest cause of cancer death in the United States. Shield […]
Read More
These drugmakers are catching up to Eli Lilly and Novo Nordisk in weight loss treatments
The lucrative market for weight loss drugs won’t stay a duopoly forever. With billions at stake, that’s pretty much been a guarantee facing the current market leaders, Eli Lilly and Novo Nordisk , from the start. But the reality of the coming competition has grown more tangible after recent announcements from rival drugmakers Roche and […]
Read More
Dexcom shares plunge more than 40%, head for worst day on record
Dexcom shares sank more than 40% on Friday and headed for their worst day ever after the diabetes management company reported disappointing revenue for the second quarter and offered weak guidance. The stock fell $45.38 to $62.47 as of early afternoon, wiping out about $18 billion in market cap. Prior to Friday, the biggest drop […]
Read More